Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials.

ABSTRACT:

Abstract

Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have seen significant treatment advancements with the emergence of Bruton tyrosine kinase inhibitors like ibrutinib. Statin use has been linked to reduced mortality in several cancers, including CLL. However, their concomitant use with targeted therapies such as ibrutinib remains unexplored. This study investigates the association of statin use with survival and adverse event outcomes in patients with CLL/SLL initiating contemporary treatment regimens, including ibrutinib. Individual participant data from 4 randomized trials-RESONATE, RESONATE-2, iLLUMINATE, and HELIOS-were used. Associations between baseline statin use and treatment outcomes were examined using Cox proportional hazards m

SUBMITTER: Abuhelwa AY 

PROVIDER: S-EPMC12275193 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature